P roprotein convertase subtilisin kexin 9 (PCSK9) inhibition with monoclonal antibodies is a promising strategy to lower low-density lipoprotein cholesterol (LDL-C) by >50% in dyslipidemic patients. 1 Homozygous familial hypercholesterolemia (HoFH), the most severe genetic disorder of lipoprotein metabolism, 2 is inadequately treated with existing lipid-lowering medications. 3
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results
The demographic and clinical characteristics of ARH patients are summarized in Table I in the online-only Data Supplement. Mean LDL-C was 278±38 mg/dL, despite maximal tolerated doses of statins and apheresis in 89% of patients. Circulating PCSK9 levels were extremely elevated in ARH at 526±31 ng/mL. 11, 12 We first assessed cell-surface LDLR expression in lymphocytes isolated from control individuals and ARH patients by flow cytometry. After mevastatin treatment, ∆ mean fluorescence intensity (MFI) levels of cell surface LDLR expression reached a maximum of 635±56 arbitrary unit (AU) in control lymphocytes. In ARH lymphocytes, cell surface LDLR levels were 3× more elevated at ∆MFI levels of 1595±215 AU (P<0.01 versus controls). PCSK9 dose dependently reduced LDLR expression down to ∆MFI levels of 150±19 AU (−76%) and 1192±96 AU (−25%), whereas alirocumab restored LDLR expression at ∆MFI levels of 548±96 AU and 1573±212 AU in control and ARH lymphocytes, respectively (Figure [A] ). Total LDLR expression in control and ARH lymphocytes was ascertained by confocal microscopy, and followed expression patterns of cell surface LDLR levels measured by flow cytometry (Figure [B] ).
We next assessed the cellular uptake of fluorescent LDL in control and ARH lymphocytes. In sharp contrast with LDLR expression patterns, LDL uptake was significantly reduced in ARH lymphocytes compared with controls. Maximal LDL uptake was observed in mevastatin-treated control lymphocytes with ∆MFI levels of 818±85 versus 532±57 AU in ARH lymphocytes (P<0.01 versus controls). PCSK9 significantly reduced LDL cellular uptake down to ∆MFI levels of 440±48 AU (−46%) and 435±44 AU (−18%) in control and ARH lymphocytes, whereas alirocumab restored LDL uptake at ∆MFI levels of 722±78 and 496±58 AU, respectively ( Figure  [C] ). Noteworthy, the levels of LDL uptake and the effects of PCSK9 treatment on LDL uptake were larger in ARH lymphocytes than in lymphocytes isolated from a receptor defective/negative HoFH patient, used as negative control ( Figure I in the online-only Data Supplement). We also ascertained that LDL uptake in lymphocytes was not altered by alirocumab alone (ie, in the absence of PCSK9; not shown).
Finally, we performed a similar series of experiments in skin fibroblasts from 1 control and 1 ARH patient, as previously described. 4, 12 We showed that ARH fibroblasts respond almost just as well to statins, PCSK9, and alirocumab than control fibroblasts, in terms of cell surface LDLR expression ( Figure 
Discussion
In the present study, we showed that despite much higher cell surface LDLR expression levels, ARH lymphocytes display sharply reduced LDL uptake capacities compared with control lymphocytes. We also showed that ARH lymphocytes were 3× less sensitive to PCSK9-mediated LDLR degradation than control lymphocytes. Consequently, ARH lymphocytes were found less responsive to alirocumab than control lymphocytes in absolute terms, suggesting that the clinical potential of PCSK9 inhibitors to lower LDL-C in ARH may be limited.
Together, our in vitro results in lymphocytes and fibroblasts are fully consistent with data from the literature showing that LDLRAP1 is required for LDLR-mediated LDL internalization in clathrin-coated pits of lymphocytes and hepatocytes but not of dermal fibroblasts. 9, 13 This rules out the use of dermal fibroblasts to test specifically the clinical potential of PCSK9 inhibition with monoclonal antibodies in ARH.
Despite the central role played by the LDLRAP1 in LDLR turnover in lymphocytes, we found that exogenous PCSK9 was able to slightly but significantly reduce LDLR expression and LDL uptake in ARH lymphocytes, albeit to a lower extent than in control lymphocytes. A small proportion of cell surface LDLR bound to PCSK9 might, for instance, be endocytosed by a mechanistic pathway not requiring clathrin and the LDLRAP1. 8 This certainly merits further investigation.
Noteworthy, just like what was observed in HoFH fibroblasts with identical LDLR defective mutations, 5,6 ARH lymphocytes responded variably to PCSK9 (−4% to −31% LDL uptake), a variation of greater relative magnitude than that observed in control lymphocytes (−35% to −54%). In this respect, we have not been able to identify any association between lymphocytes response to PCSK9 and the various LDLRAP1 mutations or any other demographic of clinical parameters of the ARH lymphocytes donors (not shown).
Despite the inherent limitation of lymphocytes as a proxy for hepatocytes, which account for the bulk of plasma LDL clearance in humans, our results suggest that PCSK9 inhibition may be beneficial for ARH patients by lowering LDL-C further, at least for some of them. In that respect, repeated injections of alirocumab 150 mg every 2 weeks were performed in 2 of our patients. There was some significant reduction in LDL-C for 1 patient (−1.1 mmol/L, ie, −11.3%) but not for the other (−0.1 mmol/L, ie, −1.8%). Another ARH patient reported in the literature failed to respond to PCSK9 inhibition with evolocumab 420 mg every month (+0.4 mmol/L, ie, +3.5%). 6 Pharmacological reductions in LDL-C of bigger magnitude (−50%) were observed in 1 ARH patient treated with the microsomal transfer protein inhibitor lomitapide. 14, 15 However, given that most ARH patients are currently receiving LDL apheresis treatments every 2 weeks, that they all display very high circulating PCSK9 levels, and that, unlike lomitapide, monoclonal antibodies targeting PCSK9 seem to cause little side effects, 1 it is probably worth testing these new therapies in ARH patients. 
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